Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 23;16:779–792. doi: 10.2147/JIR.S399043

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Bhatt et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effect of in vivo CMC 2.24 treatment on resolvin-enhancing activity in rat CFPE. CFPF were then analyzed for resolvin-enhancing activity by ELISA. RvD1 levels (ng/mL) in Cell Free Peritoneal Exudate. White bar: RvD1 levels in Normal group; Black bar: RvD1 levels in Diabetic group; Gray bar: RvD1 levels in Diabetes+CMC2.24 treatment group. N, normal group; D, diabetic group; D+CMC2.24, diabetes+CMC2.24 treatment group. Each value represents Mean (n=6-8/group) ± Standard Error (S.E.M.) *Indicates p<0.05; **Indicates p<0.01 values compared between groups at the same time period.